Caliway is dedicated to pioneering small-molecule medications catering to aesthetics and various diseases, tapping into a burgeoning market valued at over $10 billion. 

Our flagship compound, CBL-514, showcased remarkable efficacy in Phase 2 clinical trials, notably reducing subcutaneous fat by an average of 312mL in treated areas while also demonstrating promising improvements in cellulite without significant systemic side effects. Furthermore, our pipeline boasts CBL-514D, earmarked for addressing Dercum's disease, a rare condition characterized by painful lipoma growths. 
For more information, please visit: Caliway.com.tw/en

Biotechnology

Caliway Biopharmaceuticals

Org chart

Teams

Offices

Similar companies